BIOMARKERS FOR DEMENTIA DIAGNOSIS

VolverGo back

Resultados 55 results. LastUpdate Updated on 05/12/2021 [16:46:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Page1/3 nextPage   results/page


ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE NEURODEGENERATIVE DISEASE RELATED FORMS OF THE PROTEIN TDP-43

Publication No.: US2021373036A1 02/12/2021

Applicant:

UNIV ARIZONA STATE [US]

US_2019250171_A1

Absstract of: US2021373036A1

The invention relates to antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with frontotemporal dementia (FTD), but not TDP-43 associated with amyotrophic lateral sclerosis (ALS) or TDP-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with ALS, but not TDP-43 associated FTD or TDP-43 associated with healthy human brain tissue.

traducir

Bestimmung krankheitsspezifischer Protein-Aggregate in Stuhlproben

Publication No.: DE102020114278A1 02/12/2021

Applicant:

FORSCHUNGSZENTRUM JUELICH GMBH [DE]

Absstract of: DE102020114278A1

Die Erfindung betrifft Verfahren zur selektiven Quantifizierung von A-beta- bzw. alpha-Synuclein-Aggregaten umfassend die Immobilisierung von Anti-A-beta- bzw. alpha-Synuclein-Antikörper auf einem Substrat, Auftragen der zu untersuchenden Stuhlprobe auf das Substrat, Hinzufügen von für die Detektion gekennzeichneten Sonden, die durch spezifische Bindung an A-beta- bzw. alpha-Synuclein-Aggregate diese markieren und Detektion der markierten Aggregate.

traducir

METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS

Publication No.: US2021361754A1 25/11/2021

Applicant:

UNIV NEW YORK [US]

US_2018110845_A1

Absstract of: US2021361754A1

A treatment of Alzheimer's disease and other disorders involving protein misfolding or aggregation is provided by enhancing or sustaining an antibody response against predominantly directed against pathological protein aggregates or neo-epitopes present on pathogenic forms of said protein or protein complex. Furthermore, therapeutic methods are described, wherein ex vivo stimulated antigen-selected peripheral blood lymphocytes are regrafted into the cognate donor.

traducir

Compounds and methods targeting human tau

Publication No.: AU2020283534A1 25/11/2021

Applicant:

LILLY CO ELI [US]

WO_2020242963_A1

Absstract of: AU2020283534A1

The present invention provides compounds and methods targeting human tau, particularly human tau phosphorylated at threonine (217) and isoforms of tau expressed only in the CNS, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of neurodegenerative diseases such as AD, PSP and FTD.

traducir

COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34

Publication No.: US2021363232A1 25/11/2021

Applicant:

LILLY CO ELI [US]

WO_2021222025_A1

Absstract of: US2021363232A1

The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.

traducir

BLOOD BIOMARKER FOR DISCERNING BETA AMYLOID ACCUMULATION IN BRAIN

Publication No.: JP2021182000A 25/11/2021

Applicant:

ソウル大学校産学協力団SEOULNATIONALUNIVERSITYR&DBFOUNDATION

JP_2021181999_A

Absstract of: WO2018174585A2

The present application relates to a blood biomarker for discerning the cerebral deposition of amyloid beta, which is a causative material of Alzheimer's dementia. A marker according to the present application can conveniently and rapidly predictive of cerebral amyloid beta accumulation by use of a blood and can be effectively used in diagnosing relevant diseases including mild cognitive impairment at a preclinical level.

traducir

BLOOD BIOMARKER FOR DISCERNING BETA AMYLOID ACCUMULATION IN BRAIN

Publication No.: JP2021181999A 25/11/2021

Applicant:

ソウル大学校産学協力団SEOULNATIONALUNIVERSITYR&DBFOUNDATION

JP_2021182000_A

Absstract of: WO2018174585A2

The present application relates to a blood biomarker for discerning the cerebral deposition of amyloid beta, which is a causative material of Alzheimer's dementia. A marker according to the present application can conveniently and rapidly predictive of cerebral amyloid beta accumulation by use of a blood and can be effectively used in diagnosing relevant diseases including mild cognitive impairment at a preclinical level.

traducir

METHODS OF IDENTIFYING AN INDIVIDUAL AS HAVING OR BEING AT RISK OF DEVELOPING AN AMYLOID-POSITIVE DEMENTIA BASED ON MARKER MOLECULES AND RELATED USES

Publication No.: JP2021532345A 25/11/2021

Applicant:

ジェネンテック,インコーポレーテッドエフ.ホフマン−ラロシュアーゲーF.HOFFMANN−LAROCHEAKTIENGESELLSCHAFT

BR_112021000895_A2

Absstract of: WO2020016304A1

The present disclosure relates to identifying an individual as having or being at risk of developing an amyloid-positive dementia based on marker molecules amyloid β40 (Αβ40), amyloid β42 (Αβ42) and total Tau (tTau), the use of the marker molecules for the identification of an individual having or being at risk of developing an amyloid-positive dementia and a method for detecting an individual with an increased value for the combination of the marker molecules.

traducir

COMPOSITIONS AND METHODS OF DETECTION OF PRE-SYMPTOMATIC ALS

Publication No.: WO2021231887A1 18/11/2021

Applicant:

UNIV FLORIDA [US]

Absstract of: WO2021231887A1

Aspects of the disclosure relate to methods and compositions (e.g., biomarkers) useful for diagnosing pre- symptomatic amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD), and for monitoring the progression of ALS/FTD in subjects diagnosed with the disease. Methods of treating neurodegenerative diseases (e.g., ALS/FTD) are also described.

traducir

Antibody Molecules and Peptide Delivery Systems for Use in Alzheimer's Disease and Related Disorders

Publication No.: US2021355200A1 18/11/2021

Applicant:

TECHNOPHAGE INVESTIG E DESENVOLVIMENTO EM BIOTECNOLOGIA S A [PT]

JP_2018513670_A

Absstract of: US2021355200A1

The present invention relates to antibody molecules and peptide delivery systems for use in the treatment and management of Alzheimer's disease and related disorders. In particular, the antibody molecules preferentially bind oligomeric forms of beta-amyloid peptide, in single domain format, and the peptide delivery systems facilitate specific transport of such antibody molecules, as well as other cargo molecules, across the blood-brain barrier. The invention also relates to constructs of the antibody molecules and the delivery peptides, as well as pharmaceutical compositions comprising effective amounts of the antibody molecules, delivery peptides, and/or their constructs, including humanized versions of the antibody molecules and constructs. The invention further relates to methods of making these products and pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions in treating or preventing Alzheimer's and related disorders, such as those involving accumulation of beta-amyloid peptide or other peptides that aggregate in the brain; as well as to methods and kits for diagnosing these disorders.

traducir

METHODS OF USING AN ACTIVATOR OF CEREBLON FOR NEURAL CELL EXPANSION AND THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

Publication No.: JP2021178837A 18/11/2021

Applicant:

セルジーンコーポレイション

JP_2019167381_A

Absstract of: WO2015127351A1

Provided herein, for example, are methods generally relating to the expansion and/or regeneration of central nervous system (CNS) cells, such as nerve cells, astrocytes and oligodendrocytes, using an activator of cereblon (CRBN), such as an inhibitor of a CRBN substrate or downstream protein. Also provided herein, for example, are methods related to the expansion of neural stem cells, neural progenitor cells, or neural precursor cells and/or differentiation of these cells into CNS cells using a BRD7 antagonist, Ikaros antagonist, or CRBN activator. In certain embodiments, the methods further comprise differentiation of certain stem cells into the neural stem cells, neural progenitor cells, or neural precursor cells using a BRD7 antagonist, Ikaros antagonist, or CRBN activator. Also provided herein, for example, are methods of preventing or treating a CNS cell defective disease, disorder or condition, or a symptom thereof, using a BRD7 antagonist, Ikaros antagonist, or CRBN activator.

traducir

IN VITRO METHOD FOR THE DIAGNOSIS OR PROGNOSIS OF NEURODEGENERATIVE DISORDERS

Publication No.: EP3908841A1 17/11/2021

Applicant:

FUND BIOMEDICA GALICIA SUR FBGS [ES]
SERVIZO GALEGO DE SAUDE SERGAS [ES]
UNIV VIGO [ES]

WO_2020144327_A1

Absstract of: WO2020144327A1

The present invention is focused on an in vitro method for the diagnosis or prognosis of neurodegenerative disorders. The method comprises measuring the level of expression or the concentration level ofat least a lipoprotein receptor-related protein fragment (LRP fragment) or at least a lipoprotein receptor-related protein (LRP).

traducir

RhoA Pharmaceutical composition for preventing or treating dementia using phosphorylation regulation of RhoA protein

Publication No.: KR20210135382A 15/11/2021

Applicant:

한림대학교산학협력단이엘메드주식회사

Absstract of: KR20210135382A

본 발명의 RhoA 단백질에 대한 인산화 억제제를 포함하는 치매의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 따른 치매의 예방 또는 치료용 약학적 조성물은 치매를 유발하는 것으로 알려진 아밀로이드-β의 저농도 및 고농도 시의 치매 유발 경로에 각각 관여하는 RhoA 단백질의 42번째 티로신에 대한 인산화를 조절함으로써 치매를 예방, 치료 또는 개선할 수 있는 신규한 수단을 제공할 수 있다.

traducir

Method of quantifying induced membrane permeability and of screening compounds able to prevent said permeability

Publication No.: US2021349077A1 11/11/2021

Applicant:

ZARETSKY DMITRY [US]
ZARETSKAIA MARIA [US]
ZARBIO [US]

Absstract of: US2021349077A1

The present invention provides the method to quantify membrane permeability induced by various treatments including the formation of membrane pores/channels. Membrane channels created by misfolded (amyloidogenic) proteins are involved into development of various diseases, for which there is no known treatment, such as Alzheimer's disease, Amyotrophic Lateral Sclerosis, diabetes. The invention embodiments include methods to screen chemical entities for the ability to prevent increased membrane permeability. Finding chemical entities, which can prevent functioning of membrane channels formed by amyloidogenic peptides, is one of ways to develop treatments for said diseases. The invention embodiments can be used to observe the dynamics of formation of channels in biological or chemical systems where the channels are produced over time, for example to monitor channel formation by peptide fragments formed by proteases digesting full-length amyloidogenic peptides.

traducir

PEPTIDE IMMUNOGEN CONSTRUCTS DIRECTED AGAINST DIPEPTIDE REPEAT PROTEINS FROM C9ORF72

Publication No.: US2021347866A1 11/11/2021

Applicant:

UNITED NEUROSCIENCE [KY]
UNS IP HOLDINGS LLC [US]

CN_113227116_A

Absstract of: US2021347866A1

The present disclosure is directed to dipeptide repeat (DPR) peptide immunogen constructs, compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed DPR peptide immunogen constructs contain a B cell epitope derived from a DPR protein from C9orf72, including repeats of poly-GA, poly-GP, poly-GR, poly-PR, and poly-PA, linked to a heterologous T helper cell (Th) epitope directly or through an optional heterologous spacer. The B cell epitope portion of the peptide immunogen constructs contain about 10 to about 25 repeats of the respective dipeptide sequence. The disclosed peptide immunogen constructs stimulate the generation of highly specific antibodies directed against the DPR sequences. The disclosed peptide immunogen constructs can be used as an immunotherapy for patients suffering from amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and/or any other condition caused by the presence of DPRs.

traducir

MATERIALS AND METHODS FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE

Publication No.: JP2021177180A 11/11/2021

Applicant:

エレクトロフォレティクスリミテッド

JP_2018510343_A

Absstract of: WO2016146783A1

Alzheimer's disease (AD) is the most common type of dementia in aging adults with the number of people living with AD projected to increase, making the search for treatments and tools to diagnose and measure disease progression increasingly urgent. In particular, ideal biomarkers for diagnosis of AD should not only have high specificity for disease versus non-disease and high sensitivity for distinguishing between disease types but also should be able to detect changes at a very early stage of the disease. Using microglia activation as an early event of AD's onset, the present inventors have identified a panel of biomarkers in CSF which has the potential to diagnose, stage and determine the likelihood of developing AD.

traducir

METHOD OF DETECTING A NEURODEGENERATIVE DISEASE

Publication No.: CN113614531A 05/11/2021

Applicant:

新加坡国立大学国立大学医院新加坡有限公司

WO_2020157705_A1

Absstract of: WO2020157705A1

The present disclosure relates generally to the field of neurology. In particular, the disclosure relates to a method of detecting a neurodegenerative disease in a subject and methods of treatment thereof. The methods include detecting the level of an exosome-bound aggregated biomarker in a sample obtained from the subject, wherein an increased level of the exosome-bound aggregated biomarker as compared to a reference indicates that the subject is suffering from a neurodegenerative disease. Also described are methods for detecting a subject at risk of developing amyloidosis or a neurodegenerative disease, methods for detecting and treating amyloidosis or a neurodegenerative disease in a subject, and methods of determining the aggregation state of a biomarker in a sample.

traducir

AMYLOID INHIBITORY PEPTIDES

Publication No.: US2021340180A1 04/11/2021

Applicant:

UNIV MUENCHEN TECH [DE]

WO_2019234157_A1

Absstract of: US2021340180A1

The present invention relates to peptides, in particular amyloid inhibitory peptides, and to pharmaceutical compositions comprising such peptides. Furthermore, the present invention relates to such peptides, in particular such amyloid inhibitory peptides, for use in methods of treating or diagnosing neurodegenerative diseases such as Alzheimer's disease, or for use in a method of treating or diagnosing type 2 diabetes. Furthermore, the present invention also relates to a kit for the in-vitro or in-vivo detection and, optionally, quantification of amyloidogenic polypeptides, amyloid fibrils or amyloid aggregates, and/or for the diagnosis of Alzheimer's disease or type 2 diabetes in a patient.

traducir

METHODS FOR QUANTIFICATION OF AMYLOID BETA PEPTIDES IN PLASMA BY MASS SPECTROMETRY

Publication No.: WO2021219917A1 04/11/2021

Applicant:

ARACLON BIOTECH SL [ES]

Absstract of: WO2021219917A1

The present invention relates to a method for preparing a plasma sample comprising amyloid beta peptides for analysis by mass spectrometry, comprising the steps of: a) placing said plasma sample in contact with a denaturing agent, b) performing a first solid phase extraction step on the solution obtained in step a) to recover a first eluate, c) performing a second solid phase extraction step on said first eluate obtained in step b) to recover a second eluate, and d) drying said second eluate obtained in step c) and processing it for analysis by mass spectrometry, wherein the solution obtained in step d) comprises intact amyloid beta peptides Aß40 and Aß42.

traducir

COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34

Publication No.: WO2021222025A1 04/11/2021

Applicant:

LILLY CO ELI [US]

US_2021363232_A1

Absstract of: WO2021222025A1

The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.

traducir

METHODS OF TREATING BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION

Publication No.: US2021341495A1 04/11/2021

Applicant:

UNIV WASHINGTON [US]

US_2020400689_A1

Absstract of: US2021341495A1

The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

traducir

BORONDIFLUORIDE COMPLEXES OF CURCOMINOID COMPOUNDS, METHOD OF PREPARATION AND USES THEREOF

Publication No.: US2021340163A1 04/11/2021

Applicant:

UNIV AIX MARSEILLE [FR]
CENTRE NAT RECH SCIENT [FR]

JP_2019503992_A

Absstract of: US2021340163A1

The present invention relates to new borondifluoride complexes of curcuminoid compounds with an enhanced fluorescence quantum yield and emission, and their uses as fluorophore in various fields such as bioimaging, therapeutics, theranostics, display and telecommunication technologies, photovoltaics. The preparation said compounds is also described.

traducir

Biological vesicles isolation and discovery methods and systems

Publication No.: GB2594532A 03/11/2021

Applicant:

MURSLA LTD [GB]

Absstract of: GB2594532A

A method of isolating target extracellular vesicles (EVs), such as exosomes, from a biofluid comprising target EVs and non-target EVs, comprises introducing a plurality of EV capture microparticles to the biofluid, wherein the microparticles are functionalised, via a plurality of first linkers, with EV-specific binding agents (e,g antibodies against CD9, CD63, CD81, CD326, CD82, CD37 or CD41), such that a plurality of bound microparticle-EV assemblies is formed in the precursor mixture; extracting the bound microparticle-EV assemblies; introducing a plurality of target capture nanoparticles, wherein the nanoparticles are functionalised with binding agents specific to surface markers (such as disease-specific or tissue-specific markers, e.g. beta amyloid for Alzheimer’s Disease) on the target EVs, such that the nanoparticles bind to the target EVs, cleaving the plurality of first linkers to dissociate at least the target EVs from the microparticles, and then extracting the microparticles and applying at least one of dielectrophoresis or centrifugation to extract the EV-nanoparticle complexes, such that the target EVs are separated from the non-target EVs. Analogous methods using microparticles and nanoparticles functionalised with different viral-specific binding agents may be used to isolate target viruses from biofluids

traducir

Method and Apparatus for Diagnosing Alzheimer Based on Colorimetric Analysis

Publication No.: KR20210130282A 01/11/2021

Applicant:

광운대학교산학협력단

Absstract of: KR20210130282A

비색 분석 기반의 알츠하이머 판단 방법 및 그를 위한 장치를 개시한다. 본 발명의 실시예에 따른 알츠하이머 질병을 판단하기 위한 진단 키트는, 대상 물질을 포함하는 생체물질 샘플이 투입되는 샘플 패드; 상기 대상 물질의 아밀로이드 베타(Aβ: Amyloid β)와 결합될 수 있는 제1 항체가 고정된 접합 패드; 및 상기 접합 패드를 통과한 결합 물질의 형태에 따라 결합될 수 있는 제2 항체를 포함하는 적어도 하나의 테스트 영역을 포함하며, 상기 결합 물질과 상기 제2 항체가 결합 시 상기 테스트 영역이 발색되는 검출 패드를 포함할 수 있다.

traducir

p53 PEPTIDES AS MARKERS IN THE DIAGNOSIS AND PROGNOSIS OF ALZHEIMER'S DISEASE

Nº publicación: CN113574387A 29/10/2021

Applicant:

戴尔戴莫有限公司

Absstract of: WO2020178620A1

Disclosed are p53 peptides and their use as biomarkers in the diagnosis and/or prognosis of Alzheimer's disease (AD) in a biological sample. The invention also provides for a diagnostic method based on a highly accurate mass spectrometry analysis for the diagnosis of Alzheimer's disease at the pre-clinical and prodromal stages of the disease and for the prognosis of cognitive decline in a subject, by quantitating the levels of said p53 peptides specifically in human plasma of patients.

traducir

Page1/3 nextPage results/page

punteroimgGo back